Kevin Walsh

Kevin Walsh

Kevin Walsh
+1 617 570 1045

Kevin Walsh, an associate in Goodwin’s Antitrust and Competition practice, focuses his practice on advising domestic and multinational businesses and private equity firms on their obligations under the Hart-Scott-Rodino Antitrust Improvements Act and foreign merger control regimes, assessing reportability and antitrust risk for a wide variety of complex transactions involving mergers and acquisitions, license agreements, and venture capital financing.


Kevin’s recent representative experience includes:

  • Sichuan Kelun-Biotech Biopharmaceutical in its exclusive license and collaboration ADC agreement with Merck for $9.5 billion
  • Biocon Biologics in its acquisition of Viatris for approximately $3.3 billion
  • Pixomondo in its acquisition by Sony Pictures Entertainment
  • Ritchie Bros. in its acquisition of IAA, Inc. for $7.3 billion
  • TA Associates in its significant strategic growth investment in Veracode
  • Abingworth on its acquisition by Carlyle
  • Backstage Holdings in its acquisition by Cast & Crew
  • Novo in its $90 million Series B financing
  • SWORD Health in its $163 million Series D financing

Professional Experience

Prior to joining Goodwin, Kevin was an associate at Ropes & Gray LLP in Boston.

Professional Activities

Kevin is a member of the Boston and American Bar Associations.




Northeastern University School of Law


Boston College



  • Massachusetts
  • New York